A combination of anti-addiction drugs for opioids and smoking may offer the first pharmaceutical therapy to treat methamphetamine use disorder, an understudied condition that’s linked to increasing overdose deaths.
A clinical trial testing such a therapy found participants in the treatment group had a significantly better response than those in the placebo arm, according to findings published Wednesday in the New England Journal of Medicine.
The trial shows the largest effects to date for a pharmaceutical intervention to address meth use disorder,